KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Petmed Express (PETS) Current Deferred Revenue (2023 - 2025)

Petmed Express' Current Deferred Revenue history spans 3 years, with the latest figure at $800000.0 for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 33.33% year-over-year to $800000.0; the TTM value through Dec 2025 reached $800000.0, down 33.33%, while the annual FY2025 figure was $2.1 million, 19.23% down from the prior year.
  • Current Deferred Revenue reached $800000.0 in Q4 2025 per PETS's latest filing, down from $1.0 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $3.6 million in Q3 2023 to a low of $800000.0 in Q4 2025.
  • Average Current Deferred Revenue over 3 years is $2.0 million, with a median of $2.1 million recorded in 2024.
  • Peak YoY movement for Current Deferred Revenue: tumbled 60.89% in 2024, then decreased 19.23% in 2025.
  • A 3-year view of Current Deferred Revenue shows it stood at $3.1 million in 2023, then crashed by 60.89% to $1.2 million in 2024, then tumbled by 33.33% to $800000.0 in 2025.
  • Per Business Quant, the three most recent readings for PETS's Current Deferred Revenue are $800000.0 (Q4 2025), $1.0 million (Q3 2025), and $1.1 million (Q2 2025).